ImmunoGen, Inc. Announces Presentations at Upcoming EORTC-NCI-AACR Symposium

WALTHAM, Mass.--(BUSINESS WIRE)--Oct 14, 2008 - ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that the posters listed below, which have ImmunoGen authors, will be presented at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" to be held October 21-24, 2008 in Geneva, Switzerland. These posters will be presented in the poster session "Monoclonal antibodies and targeted toxins/nuclides" being held on Friday, October 24, 2008 from 12:00 - 2:00 PM CEST (6:00-8:00 AM EDT).

IMGN901

-- "Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours" (abstract #510).

This TAP compound is wholly owned by ImmunoGen. It is in clinical testing for the treatment of CD56-expressing solid tumors and multiple myeloma.

IMGN242

-- "A novel dosing strategy based on plasma levels of CanAg in a Phase II study of IMGN242 (huC242-DM4) in gastric cancer" (abstract #514).

This TAP compound also is wholly owned by ImmunoGen. It is in Phase II clinical testing for the treatment of gastric cancer.

IMGN388

-- "Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models" (abstract #529).

ImmunoGen is developing this TAP compound for the treatment of solid tumors. It entered Phase I testing during the summer of 2008. Centocor has opt-in rights.

SAR566658

-- "Preclinical evaluation of SAR566658 (huDS6-DM4) in mice bearing human tumor xenografts of breast, ovarian, lung, cervical and pancreatic cancer" (abstract #525); and

-- "In vivo stability in mice of SAR566658 (huDS6-DM4), an immunoconjugate targeting solid tumours (abstract #533).

This TAP compound is in preclinical development through the Company's collaboration with sanofi-aventis.

Linker Technology

-- "Novel antibody-maytansinoid conjugates with efficacy against multidrug resistant tumors" (abstract #518).

ImmunoGen has developed a portfolio of linkers and cell-killing agents to enable the best product design to be selected for each antibody and target. These include new linkers that provide enhanced activity against multi-drug resistant cancer cells.

Other Posters

Additional posters on TAP compounds are being presented by Company collaborators Genentech and sanofi-aventis (on trastuzumab-DM1 and SAR3419, respectively).

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's TAP technology uses antibodies to deliver one of ImmunoGen's proprietary cell-killing agents specifically to cancer targets. In addition to the Company's proprietary clinical pipeline, ImmunoGen collaborators Genentech, sanofi-aventis, Biogen Idec, and Biotest also are testing TAP compounds in the clinic, and a naked antibody is in clinical trials through the Company's collaboration with sanofi-aventis.

Contact

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and
Corporate Communications
info@immunogen.com

 

Posted: October 2008

View comments

Hide
(web5)